Furthermore, we found that PCDHGA9 suppresses EMT through TGF-β/Smad2/3 signaling and inhibits proliferation via interacting with β-catenin to antagonize the canonical Wnt pathway, revealing its role as a novel therapeutic target in GC prevention and treatment. The gene discussed is PCDHGA9; the disease is gastric cancer.